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A maioria das mortes causadas pela esclerose lateral amiotrófica (ELA) ocorrem como 
resultado de complicações respiratórias, o que significa que as provas de função 
respiratória servem como biomarcadores prognósticos nesta condição. O estudo da 
condução do nervo frénico (PNCS) é um teste rápido, não-volitivo e acessível que pode 
ser utilizado para a avaliação da função respiratória nos doentes com ELA, através da 
medição da componente motora do potencial de ação do nervo (CMAP).  
O nosso objetivo foi aferir o valor prognóstico do estudo da condução do nervo frénico 
na sua capacidade de predizer o risco de mortalidade, assim como a sua correlação com 
a capacidade vital forçada (CVF), nos doentes com ELA. 
Foi conduzida uma revisão sistemática e meta-análise que analisou oito estudos 
observacionais. Como indicador primário considerámos os hazard ratios para a 
mortalidade a diferentes limiares de amplitude de CMAP. Como indicador secundário 
considerámos a correlação entre a amplitude de CMAP e a CVF.  
Na meta-análise, verificou-se que os doentes com amplitude de CMAP igual ou inferior 
a 0.4mV tinham uma probabilidade de morrer 2.021 vezes superior, durante o período 
estudado (IC 95%= 1.161 a 3.522; I2 = 69.77%; 381 participantes). A amplitude de CMAP 
mostrou-se correlacionar positivamente com a CVF (coeficiente de correlação de 0.400; 
IC 95%= 0.226 a 0.550; I2= 69.77%; 381 participantes). Por outro lado, verificou-se uma 
correlação fraca negativa entre a latência de CMAP e a CVF (coeficiente de correlação 
de -0.235; IC 95% = 0.447 a -0.024; I2=15.92%; 112 participantes).  
Com grau moderado de evidência o nosso estudo indica que o estudo da condução do 
frénico pode ser considerado um marcador adicional da função respiratória, nos doentes 
com ELA, mas que mais investigação é necessária.  
 
 
Palavras-chave: esclerose lateral amiotrófica; nervo frénico; revisão sistemática; meta-
análise; prognóstico. 
 





The main cause of death in amyotrophic lateral sclerosis (ALS) is related to respiratory 
complications, meaning respiratory function as evaluated by dedicated tests is a relevant 
prognostic biomarkers in ALS. Phrenic nerve conduction study (PNCS) is a quick, non-
volitional, and inexpensive test that can be used to assess respiratory function in ALS 
patients by the measurement of phrenic compound muscle action potential (CMAP).  
We aimed to ascertain the prognostic value of PNCS in predicting mortality risk in ALS, 
and to test its correlation with forced vital capacity (FVC). 
A systematic review and meta-analysis examined eight observational studies. As primary 
outcome we considered the hazard ratios for mortality at different cut-off thresholds of 
the CMAP amplitude. As secondary outcomes we considered the correlation between the 
CMAP amplitude and latency with forced vital capacity (FVC). 
In the pooled analysis, patients with CMAP amplitude equal or below 0.4mV are 2.021 
more likely to die over the studied period (95%CI 1.161 to 3.522; I2=55.9%; 2 studies; 
338 participants). Amplitude of CMAP showed a moderate positive correlation with FVC 
(correlation coefficient of 0.400, 95%CI= 0.226 to 0.550; I2=69.77%; 381 participants). 
On the other hand, there was a weak negative correlation between CMAP latency and 
FVC (correlation coefficient of -0.235; 95% confidence interval= -0.447 to -0.024; 
I2=15.92%; 112 participants). 
This study gives moderate evidence in favour of PNCS as an additional marker of 
pulmonary function in ALS patients, but further research is necessary. 
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Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disease 
that involves the upper and lower motor neurons, typically affecting the limb, bulbar, and 
respiratory muscles.[10] 
Respiratory failure (RF) frequently arises in a late stage of the disease, although it can be 
the presenting feature in about 3% of the patients.[7] Patients characteristically die from 
hypoventilation[9] with hypoxaemia and hypercapnia, often precipitated by respiratory 
infection, aspiration pneumonia or bronchial impaction.[4] The median overall survival 
after symptom onset is 3 years.[25] 
Accurate assessment of pulmonary function is critical to detect early abnormalities, in 
order to estimate prognosis, provide patient counselling, and make treatment decisions.  
Although several tests that have been studied, there is no consensus on the best measure 
of pulmonary function in ALS.[21] Pulmonary function tests (PFT) are the standard 
technique used across most diseases, being non-invasive and widely available. Among 
these, forced vital capacity (FVC) seems to be the most useful measure in ALS 
management and research, as it can predict hypercapnia[35] and prognosis,[6; 9] being 
considered the ‘gold-standard’ in this context. However, PFT have notable limitations, 
namely that the technique depends on patient cooperation, which is disturbed in patients 
with less motivation, depression, or other behavioural changes, all of which are common 
in ALS.[26] Additionally, people with ALS with bulbar involvement may have facial 
weakness, which impairs an accurate assessment by PFT. Altogether this means that for 
this population the predictive ability of PFT are meaningfully compromised.[9; 16]  
Phrenic nerve conduction study (PNCS) is an alternative technique that objectively 
measures diaphragm innervation. Crucially, PNCS does not depend on patient 
collaboration and can be used irrespective of whether patients have spinal or bulbar 
involvement. In PNCS the phrenic compound muscle action potential (CMAP) is 
recorded applying a percutaneous technique. The CMAP amplitude has been shown to be 
predictive of hypoventilation, as defined by a PaCO2 > 45 mmHg,
[19] and of survival in 
ALS patients.[30; 33] Nevertheless, like other electrophysiological techniques, PNCS is not 
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as widely available as PFT, is subject to technical pitfalls, and some patients with severe 
orthopnoea are unable to tolerate the technique.  
The primary objective of this systematic review and meta-analysis was to ascertain the 





















The protocol followed the PRISMA-P guidelines[23] and was registered at Prospero 
(CRD42017079438). Reporting followed the MOOSE[40] and PRISMA guidelines[18]. 
Statistical data reporting followed the SAMPL guidelines.[17]  
 
Eligibility criteria 
Types of studies  
We considered observational studies that compared the results of the index test, PNCS, 
with the reference standard, PFT. We included studies in which data have been collected 
either prospectively or retrospectively from consecutive series of patients with ALS 
followed in any setting.  
No restrictions were made based on a minimal quality standard, minimal sample sizes, 
number of diseased cases, language, publication status or data of publication. 
Participants  
We included adults with a diagnosis of definite or probable ALS, as defined by the 
modified El Escorial criteria[4] of all ages and in any setting. According to these criteria, 
definite ALS is settled on clinical evidence of upper motor unit (UMU) (increased or tonic 
tendon reflexes, spasticity, pseudo-bulbar features, Hoffmann reflex and extensor plantar 
response) as well as lower motor neuron (LMN) (weakness, wasting, fasciculations) signs 
in the bulbar region and at least two of the other spinal regions, or the presence of UMN 
and LMN signs in three spinal regions. Probable ALS is defined based on clinical 
evidence of UMN and LMN signs at least 2 regions, with some UMN signs necessarily 
rostral to the LMN signs.  However, patients with LMN and UMN signs in one region 
and widespread signs of loss of motor units on electromyography in two or more regions 
were considered equivalent to probable category (probable-lab supported) as per revised 





Information sources and search strategy 
Electronic identification of reports was conducted in MEDLINE (via Ovid), EMBASE 
(via Ovid), and Web of Science, using the strategies outlined in Appendix 1 and Appendix 
2, from inception until October 2017. Text words and database subject headings (for 
example MeSH and EMTREE) were used in our search strategy. 
In order to identify additional published studies we checked the reference lists of studies 
included for full text revision and contact experts in the field. We excluded unpublished 
results, with the exception of conference proceedings providing that these provide 
sufficient data. 
 
Study selection  
Two independent review authors (CSS, FBR) performed the first selection based on title 
and abstract. Each author indentified the studies requiring full text review. All studies 
identified as potential eligible studies were subject to full text review (CSS, FBR). 
Disagreements were solved by discussion or by a third author (GD). Both procedures 
were performed with Covidence®.  
 
Data extraction and management  
Two independent reviewers (CSS, FBR) extracted data from the studies included in this 
review using a pre-piloted standardised electronic form. Disagreements were resolved by 
consensus or with the help of a third reviewer (GD). Another reviewer (GD) double-
checked the extracted data for prognosis.  
 
Outcomes and prioritisation  
The primary outcome was the assessment of the prognostic value of PNCS in overall 
survival. According to the type of data available, this was assessed using one or more of: 
 Pooled hazard ratios for mortality using different cut-off thresholds of the CMAP 
amplitude obtained by PNCS. 
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 Pooled mortality rates using different cut-off thresholds of the CMAP amplitude 
obtained by PNCS. Unfortunately no such data were available.  
For the primary outcome, a subgroup analysis were to be performed according to the main 
ALS phenotypical expressions (providing that sufficient data is available), as well as a 
sensitivity analysis by excluding studies deemed to be at high risk of bias.  
 
The secondary outcomes were the disease severity, based on the correlation between 
FVC, our index test, and the CMAP amplitude, as well as the correlation between FVC 
and CMAP latency.   
 
Assessment of risk of bias  
The risk of bias of included studies was evaluated independently by two review authors 
(CSS, FBR) using the QUIPS (Quality in Prognosis Studies) tool.[11; 12] 
Six domains are critical for assessing biases sufficiently large to distort the findings of 
prognosis research: (1) study participation; (2) study attrition; (3) prognostic factor 
measurement; (4) outcome measurement; (5) study confounding; and (6) statistical 
analysis and reporting. For each domain, three to seven “prompting items” are used to 
rate the adequacy of reporting by a study as “yes”, “partial”, “no”, or “unsure”; an overall 
rating for each domain is assigned as “high”, “moderate”, or “low” risk of bias. 
Disagreements were solved by discussion or with consultation of a third review author 
(GD) in case of persisting disagreement.  
 
Statistical analysis and data synthesis  
To pool hazard ratios, we used a random effects generic inverse-variance method.  
To pool the effect sizes of correlations coefficients of two continuous variables, we first 
transformed the coefficient into Fisher’s z according to formula 1. For the two studies [1; 
15] that presented a simple (i.e. univariable) linear regression, the correlation coefficient, 
r, was calculated as the square root of the coefficient of determination R2. The variance 
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of z was computed according with formula 2, and the standard error (SE) according to 
formula 3. The meta-analyses was conducted using random effect inverse-variance 
























Figure 1. Formulas for pooled analysis of correlations of continuous variables. z = Fisher’s 
score; r = correlation coefficient; vz = variance of z; n = sample size; SE = standard error.  
 
We assessed statistical heterogeneity with the I2.[13] A p-value <0.05 was considered 
statistically significant. All statistical analyses were done using Stata® (College Station, 
TX) 15.0 software.  
 
Confidence in cumulative evidence 
We evaluated the quality of the evidence using the grading of recommendations 
assessment, development and evaluation (GRADE) working group methods extended to 
prognosis factor research.[14]  
Our evaluation was based on five domains that may decrease quality: (1) study 
limitations; (2) inconsistency; (3) indirectness; (4) imprecision; and (5) publication bias; 
and two factors that may increase quality: (1) moderate or large effect size; and (2) 
exposure response gradient[14]:  
(1) Study limitations - according with the QUIPS tool for the risk of bias, outcomes 
are rated as: (1) no serious limitations for studies with low risk of bias for most of 
the bias domains; (2) serious limitations for studies at moderate or unclear risk of 
bias for most of the bias domains; (3) very serious limitations for studies at high 
risk of bias with respect to almost all of the domains. 
 
(2) Inconsistency - the quality of evidence can be downgraded if (1) the points of 
effect of the studies cross the line of no effect and their confidence intervals show 




(3) Indirectness - the quality of evidence may be downgraded when: (1) the 
participant population; (2) the prognosis factor(s); and/or (3) the outcomes 
considered in the primary studies do not fully represent the review question 
defined in the systematic review.  
 
(4) Imprecision - the quality of evidence may be downgraded if: (1) the sample size 
included in the meta-analysis is insufficient; and/or (2) there is no precise estimate 
of the effect size in the meta-analysis, due to an excessively wide confidence 
interval that overlaps the value of no effect and contain values implying that the 
prognostic factor is associated with protection or increased risk. 
 
(5) Publication bias - it should be considered for downgrading, unless the prognostic 
factor has been investigated in a large number of cohort studies.   
And two factors that may increase quality:  
(1) Moderate or large effect size – if there is a moderate or large pooled effect of the 
meta-analysis.  
(2)  Exposure response gradient – exists when elevated levels of prognostic factor 
(amount, longevity, intensity, etc) lead to a larger effect size over lower levels of 
the factor.  














A total of 345 references (MEDLINE 120, EMBASE 170, and Web of Science 55) were 
retrieved through the electronic search (Figure 2). After automatic and manual 
deduplication, 233 references had their title and abstract screened. Of these, we excluded 
204 non-illegible references. The full- texts of 29 references were examined in detail. Of 
these, 21 studies were excluded, 12 due to wrong study design, 4 due to duplication, 3 
due to wrong outcomes, 1 due to insufficient information after contacting the authors. 
Eight studies met the inclusion criteria and were included (Figure 2). No additional 
records were obtained. 
 
Figure 2. Study flow diagram of included studies.  
Records identified through database 
searching  
(n = 345)  
Additional records identified through 
other sources  
(n = 0) 
Records after  
duplicates removed  
(n = 233) 
Records screened  
(n =233) 
Records excluded  
(n = 204)  
Full-text articles  
assessed for eligibility  
(n = 29) 
Full-text articles excluded  
(n = 21) 
 Duplicated reports (n = 4) 
 Wrong study design (n = 12) 
 Wrong outcomes (n = 3) 
 Wrong patient population (n = 1) 
 Insufficient information after 
contacting the authors (n = 1) 
Studies included in  
qualitative synthesis  
(n = 8) 
Studies included in quantitative synthesis (meta-analysis)  
(n = 8) 
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Study characteristics  
Methods  
All included studies were observational: one was cross-sectional,[28] four were 
prospective cohorts,[15; 29; 39; 41] one was retrospective cohort,[33] and one was a case-
control.[38] For Bokuda et al[1] only the abstract was available and it was not possible to 
assess if the cohort was either retrospective or prospective. All were published in English, 
single-centre, and set at tertiary hospitals. Three of these studies took place in Portugal, 
two in India, two in Japan, and one in the USA. 
Participants 
The included studies involved a total of 604 participants. The main inclusion criteria 
entailed adults over 18 years old, able to give informed consent, with a diagnosis of 
definite or probable ALS, as defined by the modified El Escorial criteria. Exclusion 
criteria included patients with implantable pacemakers, cardiac insufficiency, lung 
disease, polyneuropathy, diabetes mellitus, dementia, or malignancy. The participants’ 
mean age ranged between 58.2 and 61.5 years, with a mean disease-duration between 
16.0 and 27.6 months. Bulbar involvement ranged between 22,5% and 51,16% of the 
participants. In two studies[15; 41] participants initiated non-invasive ventilation during the 
study. 
Index and reference tests 
All patients underwent FPT. From these, forced vital capacity (FVC) was assessed by 
spirometry in sitting position, and expressed in percentage of the predicted lung capacity 
adjusted for gender, weight, height and race. 
Phrenic nerve conduction studies techniques were comparable across studies. They were 
performed with percutaneous bipolar electrical stimulation of the phrenic nerve at the 
neck level (posterior to the lateral border of the sternocleidomastoid muscle, with the 
exception of one study,[41] in which stimulation was at applied at the supraclavicular 
fossa) and recorded through surface electrodes on xiphoid process (active) and costal 
margin of the mid clavicle (inactive). The ground electrode was placed over the sternum 
or ipsilateral arm. The latency of the diaphragmatic compound muscle action potentials 
(CMAP) was measured from the stimulus to the onset of potentials and expressed as 
15 
 
milliseconds (ms). The peak-to-peak amplitude of muscle action potentials were 
determined, and expressed as micro Volt (µV). 
Clinical evaluation was performed through the ALS-Functional Rating Scale-Revised 
(ALS-FRS-R), including the respiratory subscore (0-12, which includes dyspnea, 
orthpopnea, need of ventilarory assistance).   
























Bokuda 2014  Japan Longitudinal 84 N/S N/S N/S N/S N/S N/S 
Jenkins 2016 USA  Longitudinal 
prospective  




32.5 ( 8–45) 31 (31.0) Yes 
Pinto 2016 Portugal Cross-
sectional 





17.8 ± 13.6 
(5-58) 
34.98 ± 3.1 
(27–39) 
11 (26.2) No 
Pinto 2017 Portugal  Longitudinal 
prospective  






35.03 ± 3.40 9 (22.5) No 
Pinto 2012 Portugal Longitudinal 
retrospective 




N/S 31.3 ± 5.6 
(13–40) 
79 (31.1) No 
Sathyaprabha 
2010 
India  Case-control 29  
  




27.6 ± 34.3 N/S 8 (27.6) No 
Singh 2011  
  
India  Longitudinal 
prospective 
43 49.7±14.9 32 
(74.4) 
16.3 ± 15.7 44 18 (41.9) No 
Yamauchi 
2014 
Japan  Longitudinal 
prospective 
43 61.5± 12.83 21 
(48.8) 
16.4 ± 9.8 31.77± 7.22 51.16 Yes 
Table 1. Studies characteristics. N= number of participants; N/S= not specified; *Age at onset; ALSFRSR= 
amyotrophic lateral sclerosis functional rating scale-revised; NIV=non-invasive ventilation. 
 
Outcomes  
Three studies reported the hazard ratios for mortality.[1; 15; 34] However, one of these did  
not contained the enough information to be included in the analysis.[15]  
Seven studies correlated the amplitude of CMAP with FVC.[1; 15; 28; 29; 38; 39; 41] Three 
studies correlated the latency of CMAP and FVC.[29; 38; 39] For the Pinto et al 2017[29] 
study, FVC and CMAP amplitude, and FVC and CMAP latency correlation coefficients 




Synthesis of results  
In the pooled analysis, participants with CMAP amplitude equal or below 0.4mV are 
2.021 more likely to die over the studied period (95%CI 1.161 to 3.522; I2=55.9%; 2 
studies; 338 participants). 
In the pooled analysis, amplitude of CMAP showed a moderate[5] positive correlation 
with FVC (r=0.400, 95%CI= 0.226 to 0.550; I2=69.77%, 7 studies, 381 participants). On 
the other hand, there was a weak[5] negative correlation between latency of CMAP and 
FVC (r=- 0.235; 95%CI= -0.447 to -0.024; I2=15.92%; 3 studies; 112 participants)  













Figure 3. Pooled hazard ratios of mortality according with amplitude of CMAP of 0.4mV. 









Risk of bias across studies  
The overall risk of bias across studies was moderate to high (Figure 6).  
For study participation the risk of bias was moderate, with high risk in one study (Bokuda 
et al 2014[1]) due the lack of information, and five studies with a moderate risk.[28; 29; 38; 
39; 41] The information about the adequacy of study participation by eligible individuals 
was not available in none of the eight included studies. The period [1; 28; 29] and the place 
of recruitment [1; 29; 41] were not described accordingly in three studies.  
The risk of study attrition bias was high, mainly because none of the included studies 
reported information about the participants who drop-out/were lost to follow-up. 
The prognostic factor measurement item presented a moderate risk of bias. None of the 
longitudinal studies included reported a method to incorporate missing data, and the 
proportion of the data on prognostic factor available for analysis was unsure in two 
studies.[1; 29]  
The risk of bias concerning outcome measurement was low. Nevertheless, method and 
setting of outcome measurement was not the same in all participants in Jenkins et al 
2016,[15] as the stimulation intensity of the CMAP record was different in some of the 
included patients in the study. It was not clear if the method and setting of outcome 
measurement was the same in all participants in Singh et al 2011,[39] as the poor-quality 
of the spirograms in bulbar patients lead to a week of training by this subgroup of patients.  
The study confounding risk of bias was high, as none of the eight included studies   
incorporated all possible confounders (i.e. respiratory symptoms, type of onset, ALSFRS-
R, use of NIV) in the study design or data analysis.  
Figure 5. Pooled correlation coefficients between CMAP latency and FVC. 
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Finally, the risk of bias concerning the study analysis and reporting was high, as it was 
not clear if the conceptual model framework or the statistical analysis of the eight studies 
were appropriate for the design of our study. Only two studies (Bokuda et al 2014,[1] Pinto 















GRADE Quality of evidence  
The overall quality of evidence was low to moderate. Table 2 details the GRADE 
approach to the quality of the available evidence. 
PNCS probably predicts mortality. We found a moderate confidence that PNCS is 
associated with 102% relative increase in predicting mortality.  
For all three outcomes, the quality of evidence was downgraded due to the fact that the 
evidence comes from studies with moderate to high risk of bias in the majority of the 
Figure 6. Risk of bias summary.  
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domains. For mortality and correlation between FVC and CMAP amplitude, the quality 
of evidence was downgraded due to a significant heterogeneity across the studies, 
ascertained in the pooled analysis (I2 = 55.9% and I2= 69.77%, respectively). 
Additionally, for the correlation between FVC and CMAP latency, the quality of evidence 
was downgraded due to insufficient sample size included in the meta-analysis (Nº of 
participants = 112).The quality of evidence was upgraded for mortality due to high effect 
size in the meta-analysis (HR 2.02).  
Outcome 





Certainty What happens 
Mortality 
№ of participants: 
388 
(2 studies)  
HR 2.02 




We have moderate confidence that PNCS is 
associated with a 102% relative increase in 
predicting mortality 
 
PNCS probably predicts mortality 
Correlation of FVC 
and CMAP 
amplitude 
№ of participants: 
281 
(7 studies)  
r 0.40 




We have moderate confidence that CMAP 
is positively correlated with FVC 
 
CMAP levels on PNCS are probably 
positively correlated with FVC 
Correlation of FVC 
and CMAP latency 
№ of participants: 
112 





LOW a c 
We have low confidence that latency is 
negatively correlated with FVC 
 
Latency on PNCS may be negatively 
correlated with FVC 
Table 2. GRADE table summary findings 
CI: Confidence interval; HR: Hazard ratio; r: Correlation coefficient. GRADE Working Group grades of 
evidence: high certainty: we are very confident that the true effect lies close to that of the estimate of the 
effect; moderate certainty: we are moderately confident in the effect estimate: The true effect is likely to be 
close to the estimate of the effect, but there is a possibility that it is substantially different; low certainty: Our 
confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of 
the effect. Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to 
be substantially different from the estimate of effect  
 
Explanations:  
a. Downgraded due to study limitations;  
b. Downgraded due to inconsistency: large I2;  
c. Downgraded due to imprecision: optimal information size not met;  





Main findings  
Overall, we found a low to moderate evidence suggesting that PNCS have a prognosis 
value in ALS disease. This conclusion is based on eight observational studies, enrolling 
a total of 604 patients with ALS.  
PNCS probably predicts mortality in ALS. Only two of the eight included studies, 
enrolling 388 patients, reported hazard ratios for mortality. Our pooled analysis showed 
an approximately two-fold higher probability of death in patients with a CMAP amplitude 
below the 0.4mV cut-off. Significant statistical heterogeneity (I2 55.9%) was found 
among these studies, which probably was driven by differences in methodological and 
clinical features between studies. One of them[1] (Bokuda et al 2014) had only a published 
abstract, which lead to a high risk of bias, due to a lack of information regarding the study 
design and the analysis reporting. Both studies used amplitude of CMAP for the survival 
analysis, which seems to be associated with a more accurate prediction of hypoventilation 
and survival than latency[31; 33]. A 0.4 mV cut-off was considered in both studies, which 
was reported in a previous study of the same authors of one of the two papers included 
[36]. Nevertheless, a 0.3 mV cut-off was purposed by other authors [15; 37], which probably 
leaded to a higher hazard ratio for mortality.  
Although no single test has been shown to correlate well with respiratory failure in 
ALS[22], PFT are the most used measurements in clinical practise and research for 
pulmonary diseases. FVC was identified was the most relevant prognostic factor in ALS 
in most studies. Therefore, in this systematic review we looked at the correlation between, 
the FVC and PNCS parameters (amplitude and latency), in an alternatively way to 
evaluate its capacity to predict outcome in ALS patients. We found a moderate evidence 
that amplitude of CMAP is positively correlated with FVC and that latency may be 
negatively correlated with FVC. A significant heterogeneity (I2 69,77%) was found 
among the studies enrolled in the correlation of amplitude of CMAP and FVC, which has 
probably driven by differences in methodological and clinical features between studies. 
For instance, the method and setting of outcome measurement was not the same in all 
participants in Jenkins et al 2016,[15] as the stimulation intensity of the CMAP record was 
different in some of the included patients in the study. It was not clear if the method and 
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setting of outcome measurement was the same in all participants in Singh et al 2011,[39] 
as the poor-quality of the spirograms in bulbar patients lead to a week of training by this 
subgroup of patients. 
The other pulmonary function tests, such as maximal voluntary ventilation (MVV), 
maximal inspiratory (MIP) and expiratory (MEP) pressures, and nasal inspiratory 
pressure during sniff (SNIP) were not considered in this study as these tests have not show 
a consistent correlation with prognosis. MIP, despite being more sensitive to detect 
hypoventilation than FVC in ALS,[16] is negatively influenced by oro-facial paresis.[32] 
Besides that, it seems not being useful to follow patients over a long period time as it has 
a marked early decline then stabilizing (floor-effect). SNIP, despite being more suited for 




The main limitations of this study were the heterogeneity of the purposes and 
methodology standards and reporting between the primary studies. 
Clinical features of the studies, such as respiratory symptoms, ALSFRS-R, duration of 
the disease, type of onset, or NIV initiation, may contribute to the heterogeneity of the 
results. For instance, in Jenkins et al 2016, which was the study with the highest FVC and 
amplitude of CMAP correlation coefficient (0.69), patients presented a wide range of 
disease duration (2-102 months) and around 21% patients were using NIV at the time of 
the study, which may possibly influence the results.  
 
Implications for research  
Sub-group analysis was not performed due to a lack of data of the individual studies. 
However, it would be interesting to compare spinal and bulbar onset subgroups regarding 
the PCNS prognosis impact. This would be relevant mainly for bulbar subgroup, which 




It would be also relevant analyse the specific impact of PNCS in NIV initiation, as this is 
the intervention that has been shown that improves survival,[3] proportionally to duration 
of use,[27] as well as quality of life.[2; 3]  
We opted for the prognosis value analysis of PNCS, as we considered the higher impact 
on the clinical practise. Despite this, the diagnosis accuracy of the test should be evaluate 
in a subsequent study.   
Larger cohort studies with the complete follow-up, unbiased case selection and complete 
ascertainment of the possible confounders need to be performed in order to ascertain the 
capacity of PNCS in predicting ALS outcome.  
 
Implications for practice  
Further research is needed in order to validate PNCS as a biomarker of pulmonary 
function in ALS.  
Including retrospective studies can be confounding due to the fact that it tends to include 
a large number of covariates that are related and can influence the biomarker.[8] For 
instance, the presence and the type of respiratory symptoms, the age of the patient, the 
duration of the disease, the type of onset, the functional status, the use of NIV are some 
of the potential confounders that should be considered in the data analysis.  
Besides of that, the studies tend to include a multiplicity of clinical endpoints (i.e. FVC, 
MVV, MIP, MEP, SNIP, CMAP) in their analysis, which lead do higher level of false-
positive associations. An analysis that prioritizes the relevant endpoint and uses a 
methodology that controls the family-wise error rate is necessary.[8]    
Regarding the technique itself, like other electrophysiological techniques, PNCS is highly 
operator-dependent and its results depend on the quality of its performance and 
standardization of the technique is essential for the interpretation of the results. 
In summary, improvements of standardization of the technique and using statistical 
methodologies that have inherent confounding and multiplicity in consideration are 





Our study suggest that PNCS can probably be used as an additional marker of pulmonary 
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Appendix 1 – Fundamentação teórica  
A esclerose lateral amiotrófica é uma doença neurodegenerativa rapidamente progressiva 
que envolve quer os neurónios motores superiores quanto inferiores. A maioria das 
mortes causadas por esta doença ocorrem como resultado de complicações respiratórias. 
Nesse sentido as provas de função respiratória servem como biomarcadores prognósticos 
nesta condição, essenciais para definir prognóstico, aconselhar os doentes e cuidadores e 
tomar decisões terapêuticas, tais como o início da ventilação não invasiva (NIV). Embora 
nenhum teste seja um gold-standard para avaliação da função respiratória nos doentes 
com ELA, dos parâmetros respiratórios, a capacidade vital forçada (CVF) é aquele que é 
utilizado com maior frequência na prática clínica e investigacional.  
O estudo da condução do nervo frénico (PNCS) é um teste rápido, não-volitivo e acessível 
que pode ser utilizado para a avaliação da função respiratória nos doentes com ELA. 
Apresenta como vantagem em relação às provas de função respiratória, o facto de não 
depender da colaboração dos doentes, o que é útil em doentes com envolvimento bulbar, 
que apresentam paresia orofacial, e naquelas com distúrbios cognitivos, frequentes nesta 
doença. A latência e a amplitude da componente motora do potencial de ação são aferidos 
com este teste. Destes, a amplitude (CMAP) mostrou ser aquela que prediz hipoventilação 
(definida por PaCO2 > 45 mmHg) e sobrevida nos doentes com ELA. 
Posto isto, o nosso objetivo com este trabalho foi aferir o valor prognóstico do estudo da 
condução do nervo frénico na sua capacidade de predizer o risco de mortalidade, assim 
como a sua correlação com a capacidade vital forçada (CVF), nos doentes com ELA. 
Conduzimos uma revisão sistemática de estudos observacionais que comparavam os 
resultados do nosso teste em estudo, PNCS, e o teste de referência, PFR, em adultos com 
diagnóstico definitivo ou provável de ELA, como definido pelos critérios El Escorial. 
Pesquisámos nas bases de dados MEDLINE (pela Ovid), EMBASE (pela Ovid), e Web 
of Science até Outubro de 2017. Dois revisores independentes reviram os títulos e 
resumos, os textos completos e fizeram a extração dos dados de prognóstico, utilizando o 
Covidence®. Considerámos como resultados de prognóstico: os hazard ratios para 
mortalidade para diferentes cut-offs de amplitude de CMAP, assim como a correlação 
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entre a FVC e a amplitude, e a entre o FVC e a latência do CMAP. O risco de viés foi 
avaliado utilizando a ferramenta Quality In Prognosis Studies (QUIPS). Para efetuar a 
meta-análise dos hazard ratios, utilizámos o método do inverso da variância para efeitos 
aleatórios. Para os resultados de medida de efeito de variáveis contínuas, transformámos 
o coeficiente de correlação na escala de z de Fisher, e efetuámos a meta-análise utilizando 
o método do inverso da variância, apresentando os resultados convertidos de novo a 
correlações. A heterogeneidade dos resultados foi avaliada com I2. Foi considerado um 
valor de p<0.05 como estatisticamente significativo. Avaliámos a qualidade da evidência 
utilizando o Grading of Recommendations Assessment, Development and Evaluation 
(GRADE), aplicado a estudos de avaliação prognóstica. 
Um total de 365 referências (MEDLINE 210, EMBASE 170, Web of Science 55) foram 
obtidas pela pesquisa eletrónica. Após exclusão das referências repetidas, 233 foram 
obtidas para revisão por título e resumo. Destas, excluímos 204 referências. O texto 
completo de 29 referências foi examinado. Destes, 21 estudos foram excluídos. Oito 
estudos cumpriam os critérios de inclusão. Todos eles são estudos observacionais, 
incluindo um total de 604 participantes. A idade destes variou entre 58,2 e 61,5 anos, com 
uma duração de doença entre os 16,0 e 27,6 meses. O envolvimento bulbar variou entre 
22,5% a 51,6%. Em dois dos estudos, os doentes iniciaram ventilação não-invasiva.  
Na meta-análise, verificou-se que os doentes com amplitude de CMAP igual ou inferior 
a 0.4mV tinham uma probabilidade de morrer 2.021 vezes superior, durante o período 
estudado (IC 95%= 1.161 a 3.522; I2 = 69.77%; 381 participantes). A amplitude de CMAP 
mostrou-se correlacionar positivamente com a CVF (coeficiente de correlação de 0.400; 
IC 95%= 0.226 a 0.550; I2= 69.77%; 381 participantes). Por outro lado, verificou-se uma 
correlação fraca negativa entre a latência de CMAP e a CVF (coeficiente de correlação 
de -0.235; IC 95% = 0.447 a -0.024; I2=15.92%; 112 participantes). O risco de viés aferido 
pela ferramenta GRADE foi moderado a elevado, verificando maior risco de viés nos 
domínios study attrition, study confounding e study analysis and reporting. O grau de 
evidência aferido pelo GRADE baixo a moderado: moderado para o hazard ratio de 
mortalidade e correlação da amplitude de CMAP com a CVF; baixa para a correlação 
entre a latência de CMAP e a CVF.  
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Uma evidência moderada indica que o estudo da condução do frénico pode ser 
considerado um marcador adicional da função respiratória, nos doentes com ELA, mas 
que mais investigação é necessária. 
Dos oitos estudos incluídos, apenas dois reportavam uma análise de mortalidade 
relacionada com o PNCS, o nosso outcome primário, sendo que um deles apenas o 
abstract está publicado, pelo que a escassez de dados quanto ao desenho do estudo e da 
análise dos dados. Quer para a mortalidade quer para a correlação entre a amplitude do 
CMAP e a CVF, constatou-se uma significativa heterogeneidade estatística (I2 69,77% e 
55,9%, respectivamente), provavelmente devida às diferenças nas características clínicas 
e metodológicas dos estudos incluídos. 
Nenhum dos estudos incluiu possíveis fatores confundidores no desenho do estudo, tais 
como a presença ou ausência de sintomas respiratórios, o score de ALSFRS-R, a duração 
da doença, o tipo de início (espinhal ou bulbar), ou a iniciação de ventilação não invasiva. 
Para além do mais, a maioria dos estudos inclui uma miríade de variáveis respiratórias 
(tais como, volume ventilatório máximo, pressão inspiratória máxima, pressão expiratória 
máxima, pressão inspiratória nasal) que conduz a uma maior percentagem de associações 
de falsos-positivos. É necessária uma análise que priorize os outcomes e recorra a uma 
metodologia que reduza o erro do tipo I. Outro fator a ter em conta diz respeito à técnica 
em si. O estudo do nervo frénico é altamente operador-dependente e como tal os seus 
resultados dependem da qualidade da sua concretização. É necessária uma 
estandardização e difusão da técnica para que esta possa ser aplicada na prática clínica de 
forma regular.  
Embora não tenha sido incluída neste estudo por falta de dados, a sub-análise de grupo, 
espinhal e bulbar, seria importante uma vez que os doentes bulbares, pela sua menor 
compliance com as PFR, beneficiariam do PNCS. Além disso seria relevante avaliar o 
impacto do PNCS na decisão de início de ventilação não-invasiva, uma vez que esta é 
uma intervenção que mostrou melhorar sobrevida e qualidade de vida. Do mesmo modo, 
a avaliação da acuidade diagnóstica do PNCS deveria ser avaliada num estudo 
subsequente.  
Em suma, o nosso estudo sugere que o PNCS provavelmente pode ser utilizado como 
biomarcador adicional da função pulmonar nos doentes com ELA. Contudo, coortes de 
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maiores dimensões, com o seguimento completo, sem viés de seleção, com inclusão e 
devida análise dos possíveis fatores confundidores são necessários para a validação do 

























Appendix 2 - MEDLINE search strategy 
1. exp Phrenic Nerve/ 
2. phrenic$.tw. 
3. or/1-2 
4. exp Motor Neuron Disease/ 
5. (moto$1 neuron$1 disease$1 or moto? neuron$1 disease).ti,ab. 
6. ((Charcot$1 adj5 syndrome$1) or (Lou Gehrig$1 adj5 syndrome$1)).ti,ab. 
7. ((Charcot$1 adj5 disease) or (Lou Gehrig$1 adj5 disease)).ti,ab. 
8. Amyotrophic Lateral Sclerosis.ti,ab. 
9. or/4-8 
10. and/3,9 
11. (animals not (animals and humans)).sh. 






















Appendix 3 - EMBASE search strategy 
1. exp Phrenic Nerve/ 
2. phrenic$.tw. 
3. or/1-2 
4. exp Motor Neuron Disease/ 
5. (moto$1 neuron$1 disease$1 or moto$1 neuron$1 disease).ti,ab. 
6. ((Charcot$1 adj5 syndrome$1) or (Lou Gehrig$1 adj5 syndrome$1)).ti,ab. 
7. ((Charcot$1 adj5 disease) or (Lou Gehrig$1 adj5 disease)).ti,ab. 
8. Amyotrophic Lateral Sclerosis.ti,ab. 
9. or/4-8 
10. and/3,9 
11. nonhuman/ not human/ 
12. 10 not 11 
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Appendix 4 – Web of Science search strategy 
1. TI=(phrenic) AND TI= (motor neuron) OR amyotrophic OR Charcot OR Lou 
Gehrig) 
 
